Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTVOE6D)

DTT Name	Mitogen-activated protein kinase (MAPK) DTT Info
Gene Name	MAPK

Molecule-Related Drug & Molecule List

Molecule-Related Drug List

Molecule Type:

DTT

DTP

DME

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

3 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GBL-310	DM2IFJQ	Keratosis	ED56	Phase 2	[1]
LTT462	DM94E6W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
PF-07799544	DMAO10K	Aggressive cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------

18 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bidentate ligands of Markush derivative 1	DMB08D3	N. A.	N. A.	Patented	[4]
Bidentate ligands of Markush derivative 2	DM2QNMC	N. A.	N. A.	Patented	[4]
PMID25991433-Compound-B1	DMJTO69	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-B2	DMTYQOF	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-B3	DMWSGV2	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-C2	DMOAU09	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-C3	DMSKWBE	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-F1	DMFS2YL	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-J1	DMQGUMN	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-J6	DMOWULJ	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L	DM5U8WT	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-N2	DMXY4BE	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-P2	DMEGS7U	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-P3	DMAFZLP	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-Q1	DMEMSB2	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-Q2	DMAIKJV	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 18 Patented Agent(s)

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
U0126	DM31OGF	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Molecule Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

References

1	WO patent application no. 2010,0456,51, Methods for analyzing drug response.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
4	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
5	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
6	Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11569-74.